Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | CA7 | P43166 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4387282 | 0.78 | PRNP (0.42) | CA1CA2CA12CA7CA9 | |
| SCHEMBL7529954 | 0.76 | CYP1A2 (0.40) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1035933 | 0.76 | CYP1A2 (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2579070 | 0.76 | TTR (0.42) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28062208 | 0.75 | CYP3A4 (0.52) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28146524 | 0.74 | MEN1 (0.63) | CA1CA2CA12CA7CA9 | |
| SCHEMBL289536 | 0.74 | CA12 (0.64) | CA1CA2CA12CA7CA9 | |
| SCHEMBL15523819 | 0.74 | CA1 (0.50) | CA1CA2CA12CA7CA9 | |
| Hydrochloric Acid SCHEMBL11052779 | 0.74 | CYP1A2 (0.38) | CA1CA2CA12CA7CA9 | |
| SCHEMBL588970 | 0.74 | CYP1A2 (0.45) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112973448-B | Composite reverse osmosis membrane with chlorine resistance body, preparation method and application thereof | 南京理工大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-112973449-B | Polyester composite reverse osmosis membrane with chlorine resistance as body and preparation method and application thereof | 南京理工大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-112973448-A | Composite reverse osmosis membrane with chlorine resistance body, preparation method and application thereof | 南京理工大学 | 2021-06-18 | — | — | CN | disclosed |
| CN-112973449-A | Polyester composite reverse osmosis membrane with chlorine resistance and preparation method and application thereof | 南京理工大学 | 2021-06-18 | — | — | CN | disclosed |
| CN-101687886-B | Seven-membered ring compound and pharmaceutical application thereof in preventing and treating diabetes and metabolic syndrome | SHANGHAI INST MATERIA MEDICA | 2012-11-07 | — | — | CN | disclosed |
| US-8158623-B2 | Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2012-04-17 | — | — | US | disclosed |
| US-8158623-B2 | Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2012-04-17 | — | — | US | disclosed |
| US-8158623-B2 | Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2012-04-17 | — | — | US | disclosed |
| US-20100173905-A1 | HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE | 2010-07-08 | — | — | US | disclosed |
| US-20100173905-A1 | HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE | 2010-07-08 | — | — | US | disclosed |
| US-20100173905-A1 | HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE | 2010-07-08 | — | — | US | disclosed |
| EP-2199295-A1 | COMPOUNDS WITH 7-MEMBER CYCLE AND THE PHARMACEUTICAL USE THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLISM SYNDROME | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2010-06-23 | — | — | EP | disclosed |
| EP-2199295-A1 | COMPOUNDS WITH 7-MEMBER CYCLE AND THE PHARMACEUTICAL USE THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLISM SYNDROME | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2010-06-23 | — | — | EP | disclosed |
| US-20100055043-A1 | Poly-Halo Metal X-ray Contrast Agents | MALLINCKRODT INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100055043-A1 | Poly-Halo Metal X-ray Contrast Agents | MALLINCKRODT INC. | 2010-03-04 | — | — | US | disclosed |
| WO-2008060399-A2 | X-RAY CONTRAST AGENTS COMPRISING A METAL CHELATE AND A POLYHALOGENATED PHENOL, THIOPHENOL, RESORCINOL, THIORESORCINOL OR DITHIORESORCINOL | MALLINCKRODT INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173905-A1 | HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME | GPR119, CYP11B1, HSD11B1 | CA1 4162/4885CA2 3220/4885CA12 3301/4885 |
| US-20100055043-A1 | Poly-Halo Metal X-ray Contrast Agents | SLC39A3, ZNF277, TPR | CA1 1452/4885CA2 1342/4885CA12 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.